Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- cardiac
- Technical Know How
- Disease
- Blood Clotting
- Therapeutic
- Surgical
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 282942
Eptifibatide shall refer to a specific peptide designated by Licensee and known as eptifibatide, which same peptide was known previously as Integrilin or Integrelin, the chemical structure of which is known to Licensor because of the prior business relationship between Licensee and Licensor.
Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries).
IPSCIO Record ID: 291124
Licensor shall not engage in, or enable any third party to engage in, any commercialization, licensing, manufacturing, marketing or sales activity with respect to the application of Licensor Know-how or the Licensed Process to Integrelin with or on behalf of any third party without Licensees prior written consent. This agreement includes a non-exclusive grant back to Licensor from Licensee.
Licensee owns certain patent rights, trademarks and know-how relating to a product called Integrelin(TM).
Bulk Product shall mean a bulk peptide product which contains Integrelin, is produced by the Licensed Process and is intended to undergo further processing, formulation and/or vialing and packaging.
Integrelin shall mean a specific peptide designated by Licensee and known as Integrelin(TM),
IPSCIO Record ID: 203519
The Parties wish to terminate Licensors role in the commercialization and manufacturing of INTEGRILIN in and for the Transferring Territory, and to have Licensors existing regulatory approvals and authorizations, contractual rights and responsibilities transferred in an appropriate manner to a new commercial licensee that this Licensee will identify.
This agreement, terminates certain License rights and modifies other certain license rights terms. For the Modification of IP Licenses Granted to Licensee
– the exclusive licenses under the Licensor Patents granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN Products in the relevant country or countries or in the Transferring Territory, as applicable;
– the non-exclusive licenses under the Licensor Patents granted in the Collaboration Agreement with respect to the Manufacture of INTEGRILIN Products shall be exclusive, except as to Licensor and its Affiliates, with respect to the Manufacture of INTEGRILIN Products for distribution, use and/or sale in the relevant country or countries or in the Transferring Territory,
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement with respect to Manufacturing INTEGRILIN Products shall be exclusive, except as to Licensor solely with respect to Manufacturing INTEGRILIN Products in or for the relevant country or countries or in or for the Transferring Territory.
For Certain Copyrights and Trademarks, Licensor grants to Licensee and the New Commercial Licensee an exclusive, perpetual, sublicensable license under Licensors copyrights in all Marketing Materials solely for use in Commercializing INTEGRILIN Products in the Transferring Territory.
The Trademark means all registrations, applications for registration and other rights in and to the INTEGRILIN mark and the APEREXIN back-up mark for the Development, Manufacture and Commercialization of INTEGRILIN Products in or for the Transferring Territory.
The New Commercial Agreement means a definitive agreement between Licensee and a Pharmaceutical Company under which such Pharmaceutical Company is granted a license to INTEGRILIN Products and assumes primary responsibility for the Development and Commercialization of the INTEGRILIN Products in and for the Transferring Territory, and the Manufacture of the INTEGRILIN Products for Development and Commercialization in the Transferring Territory.
IPSCIO Record ID: 352721
In order to establish Licensor/Manufacturer of Belgium as a preferred supplier of the Product on a commercial basis, Manufacturer shall perform the development and manufacture of the Product in its premises in Belgium according to the terms.
Manufacturer Technical Information shall mean
– unpatented proprietary and confidential technical information, specifications, compositions, manufacturing methods, application methods, testing methods, computer programs,technical data and drawing as well as any improvements thereto.
– patents and patent applications on any of the foregoing, including divisions, owned by, or licensed or assigned to Manufacturer, and based on inventions which are either actually reduced to practice or constructively reduced to practice by filing a patent application on such invention prior to the termination of this Agreement, continuations, continuations in part, extensions, amendments and reissues thereof.
Bivalirudin shall mean the 20 amino acid polypeptide corresponding to LC13 Code Name SP071 and/or SF220.
Chemilog shall mean the process by which Bivalirudin API is manufactured.
Product shall mean the fully chemically synthetized Bivalirudin API either through Manufacturers existing process or the Chemilog Process.
Licensor manufactured two validation batches of Angiomax bulk drug substance using the Chemilog proces.
Angiomax directly blocks or inhibits the actions of thrombin, a key component in
the formation and growth of blood clots.
(Angiomax(R)) and is developing and marketing pharmaceutical compositions containing Bivalirudin for the treatment of PTCA and other diseases.
Angiomax is for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty.
Angiomax has
– reduced the frequency of life-threatening coronary events including heart attack and the need for emergency coronary procedures;
– reduced the likelihood of major bleeding and the need for blood transfusion;
– demonstrated a predictable anticoagulant response to a specific Angiomax dose, which enables simplified dosing; and
– been used in combination with GP IIb/IIIa inhibitors and other products used in angioplasty
IPSCIO Record ID: 117698
With this amendment the Parties desire to modify their agreement to address such issue of sales allocation, and also with respect to the allocation of regulatory responsibilities in Canada, the manufacture and supply of Integrilin Product in Canada, and to set forth certain understandings regarding a Phase III clinical trial for Integrilin Product in the setting of acute myocardial infarction or AMI.
INTEGRILIN is indicated for the treatment of patients with an acute coronary syndrome and patients who undergo angioplasty procedures. The acute coronary syndrome indication includes patients with unstable angina and non-Q-wave myocardial infarction, whether they receive medical treatment or undergo angioplasty.
Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.
Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.
IPSCIO Record ID: 28285
